Landon C. Brown

Landon C. Brown

Oncology
1021 Morehead Medical Drive
Building 1, Suite 5300
Charlotte, NC 28204

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy.

The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy.

Journal: BJUI compass
Published: July 17, 2026

Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.

Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.

Journal: Cancer research communications
Published: April 03, 2026

From Intern to Fellow: A Bibliometric Analysis of Research Trends Among Matched Gastroenterology Fellows.

From Intern to Fellow: A Bibliometric Analysis of Research Trends Among Matched Gastroenterology Fellows.

Journal: Digestive diseases and sciences
Published: March 20, 2026

Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial.

Circulating Tumor Cells and Clinical Outcomes in Men with Metastatic Castration-sensitive Prostate Cancer Treated with Enzalutamide and Docetaxel: An Analysis of the ENZADA Trial.

Journal: European urology open science
Published: August 20, 2025

Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial.

Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial.

Journal: Clinical genitourinary cancer
Published: November 01, 2024

Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.

Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy.

Journal: Clinical genitourinary cancer
Published: February 09, 2024

RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.

RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.

Journal: JCO precision oncology
Published: December 07, 2023

Pediatric ERCP: Factors for Success and Complication-A 17-Year, Multisite Experience.

Pediatric ERCP: Factors for Success and Complication-A 17-Year, Multisite Experience.

Journal: Journal of pediatric gastroenterology and nutrition
Published: July 03, 2023

Germline Testing in Prostate Cancer: Implementation and Disparities of Care.

Germline Testing in Prostate Cancer: Implementation and Disparities of Care.

Journal: JCO oncology practice
Published: January 31, 2023

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: September 16, 2022

Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.

Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.

Journal: Translational andrology and urology
Published: July 25, 2022

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

Journal: Cancers
Published: June 21, 2022
Showing 1-12 of 33

Last Updated: 09/26/2026